David Proia
About David Proia
David Proia Education and Expertise
David Proia holds a Ph.D. in molecular and cellular biology from Baylor College of Medicine. He also has a B.S. in biochemistry from Worcester Polytechnic Institute. His academic background has provided him with a strong foundation in biology and drug discovery. He leverages his extensive knowledge in molecular and cellular biology to advance various pharmaceutical and therapeutic projects.
David Proia Professional Background
David Proia has an extensive professional background in the field of oncology and drug discovery. He has held significant positions in leading biotechnology companies. Notably, he served as Vice President of Oncology at ROME Therapeutics, where he was the biology lead for developing agents targeting endogenous reverse transcriptase. He has also worked as Senior Director of In Vivo Pharmacology at C4 Therapeutics, and as Director of Cancer Biology and In Vivo Pharmacology at Synta Pharmaceuticals. Earlier in his career, he was a Scientist at AstraZeneca.
David Proia Contributions to Oncology Programs
During his tenure at C4 Therapeutics, David Proia was a project leader on multiple oncology programs. One of the notable projects he led is CFT7455, an IKZF1/3 degrader, which is currently in clinical trials for patients with multiple myeloma and non-Hodgkin’s lymphoma. His work has contributed to advancing both early and later stage clinical development in the field of oncology.
David Proia Peer-Reviewed Publications
David Proia has an impressive record of over 40 peer-reviewed publications. His contributions to scientific literature reflect his extensive research experience and the impactful nature of his work in molecular and cellular biology, as well as oncology drug discovery. These publications serve as a testament to his expertise and influence in the scientific community.